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Neville D Yeomans1,2Abstract
In a recently published article in BMC Medicine, Scarpignato and colleagues present the results of a consensus
conference that addressed several aspects of the management of pain in patients with osteoarthritis. The main areas
covered include the relative safety in regard to gastrointestinal and cardiovascular adverse events of non-selective
‘traditional’ non-steroidal anti-inflammatory drugs (NSAIDs) versus cyclooxygenase-2 selective NSAIDs. The role of
co-therapy with proton pump inhibitors in enhancing gastrointestinal safety is also reviewed.
This commentary focuses on two areas that the consensus conference addressed, i) the whole length of gastrointestinal
tract risk profile of the various NSAIDs (not just the ulcer risks in stomach and duodenum); ii) more recent information,
but still some uncertainties, about the cardiovascular risks associated with the two classes of NSAID in general, and
naproxen in particular.
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As life expectancy in many countries increases into the
80s and beyond, degenerative joint disease is creating an
increasing burden for patients and healthcare systems. For
osteoarthritis especially, non-steroidal anti-inflammatory
agents (NSAID) remain the most effective option for pain
relief, short of surgical alternatives such as joint replace-
ment [1]. However, gastrointestinal (GI) ulcers and their
complications are well-known NSAID side effects that
are more prevalent in the elderly and are, at times, life-
threatening [2].
The recognition that NSAIDS damage the stomach and
duodenum (at least partly) by blocking the mucosal produc-
tion of protective prostaglandins catalyzed by cyclooxygen-
ase (COX)-1 [3] led to the development of COX-1-sparing
NSAIDs. These selectively inhibit COX-2, which mediates
synthesis of pro-inflammatory prostaglandins. The strategy
has been successful: highly selective COX-2 inhibitors doCorrespondence: n.yeomans@uws.edu.au
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unless otherwise stated.reduce (but do not eliminate) the risk of GI ulceration [4,5].
However, an unanticipated risk that surfaced in several ran-
domized studies was an increase in adverse cardiovascular
(CV) events in patients taking COX-2 inhibitors for months
or years [6-8]. The European Medicines Agency responded
promptly, stating, in 2005, that ‘COX-2 inhibitors must not
be used in patients with established ischaemic heart disease
and/or cerebrovascular disease …’ [9]. On the other hand,
the US Food and Drug Agency (FDA), in the same year, de-
clined to make such a limiting statement – noting that it
was unclear whether COX-2 inhibitors carried a greater vas-
cular risk than the older non-selective NSAIDs (nsNSAIDs),
that further research was required, and that in the meantime
warnings about the possibility of increased CV risk with all
NSAIDs should be included in drug labeling [10].
Thus, clinicians and their patients face some dilemmas
about how to balance the GI and CV risks, especially in
patients known to be at increased risk for both, as occurs
in many elderly patients. Cryer, in a submission on behalf
of consumers to a 2014 FDA hearing that was contemplat-
ing a labeling change based solely on CV risk, emphasized
the need for a comprehensive risk assessment: ‘In theis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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of NSAID use, which we applaud, we […] would not want
you to inadvertently increase the risk of other untoward
outcomes associated with NSAIDs, such as GI and renal
toxicities’ [11].
It is timely to review the area; thus, in a recent article
published in BMC Medicine, Scarpignato et al. [12] re-
port on a recent consensus meeting that has updated
earlier guidelines using more recent information.
Discussion
Scarpignato et al. [12] used a modified Delphi approach
to gauge levels of agreement and opinions on the level
of evidence for nine statements about various aspects of
NSAID use. These ranged from efficacy for pain relief, a
comparison of GI risks with different NSAIDs, to a com-
parison of the CV risks with different NSAIDS. The
panel was an international multidisciplinary group. It is
perhaps a pity that their meeting was now more than
three years ago, but the authors updated their literature
search in the interval for this publication. The result is a
helpful distillation of expert opinion on the areas cov-
ered. This commentary will focus on two aspects. Firstly,
the consensus statement looks more comprehensively
than others at the GI risks of NSAIDS from top to bot-
tom of the GI tract. While the life threatening complica-
tions of NSAIDS (including low-dose aspirin) arise
mainly from ulcers in the stomach and duodenum, it is
increasingly recognized that small intestinal ulceration is
also common as one cause of iron-deficiency anemia in
NSAID users and, occasionally, of frank GI hemorrhage.
Looking at GI risk in its totality, statement 4 from the
consensus conference reads in part: ‘NSAID use is asso-
ciated with increased risk of adverse events throughout
the entire GI tract.’ The levels of agreement and of sup-
porting evidence were both high. There is good evidence,
summarized in the consensus paper, that proton pump in-
hibitors (PPI) substantially reduce the risk of upper GI ul-
ceration and complications of both nsNSAIDs and COX-2
inhibitors. However, it is not surprising that current evi-
dence (rated level B by the conference) indicates that PPIs
do not protect against ulceration in the near neutral pH
milieu of the small intestine and colon.
The second issue worthy of comment is the conclu-
sion the consensus group reached about whether some
NSAIDs are safer than others from the standpoint of CV
risk. Statement 8 reads: ‘The risk of CV events associated
with celecoxib use is similar to that associated with the
use of most ns-NSAIDs.’ Eighty-four percent of the panel
agreed strongly or moderately, although only just over
half the panel rated the level of evidence as high. They
did not endorse earlier strong recommendations from
bodies such as the American Heart Association and
American College of Gastroenterology that naproxenshould be the NSAID of choice for patients with high
CV risk [13-16]. Instead, the treatment-guidance algo-
rithm they propose allows either naproxen or low-dose
celecoxib as the preferred agents in patients with high
CV risk, adding in a PPI to either if patients are judged
to also be at high GI risk.
As Scarpignato et al. [12] indicate, the evidence about
whether naproxen has a lower CV risk has been conflict-
ing; there is some pharmacokinetic basis to suspect it
might. Aspirin exerts its prolonged anti-platelet effect be-
cause it irreversibly acetylates platelet cyclooxygenase [17].
However, other nsNSAIDs are reversible inhibitors of the
enzyme, so their platelet inhibitory effect disappears as
their plasma levels dissipate [18]. Naproxen is one of the
longer acting nsNSAIDs, with a plasma elimination half-
life of about 14 hours [19]; a small study of volunteers
given a single dose of 1,000 mg found platelet aggregation
still reduced after 24 hours in 60% of cases [20]. Thus, it is
plausible that twice daily dosing may offer some protection
against thrombotic events.
Seemingly in support of this, a recent large meta-analysis
(the CNT collaboration) found that a coxib, diclofenac, or
ibuprofen increased the rate of major vascular events by
about a third (not quite significant for ibuprofen), but na-
proxen did not [21]. However, a meta-analysis is only as
strong as its component parts, and a particular weakness
of the CNT meta-analysis was that it had to indirectly
compare the effects of the different drugs. That is to say,
studies of drug A versus drug B were combined with stud-
ies of drug A versus placebo to estimate relative risks for
drug B versus placebo.
As Scarpignato et al. [12] note, and a recent FDA hearing
concluded, the best evidence should come from a large
randomized controlled trial in arthritis patients at high CV
risk; such a study is now nearing completion [22]. The Pro-
spective Randomized Evaluation of Celecoxib Integrated
Safety versus Ibuprofen Or Naproxen (PRECISION) trial,
which was mandated by the FDA, has recruited more than
20,000 such patients. The last patient follow-up is sched-
uled for the end of 2015, so results can be anticipated dur-
ing 2016 [23]. This study should give useful, real-world
information to increase the evidence base for managing
the high CV risk arthritis patient.Conclusions
Scarpignato et al. [12] have produced a valuable sum-
mary of the current state of knowledge about the GI and
CV risks of both nsNSAIDs and COX-2 selective drugs,
which will be helpful for clinicians managing patients
with osteoarthritis. As they emphasize, there are still un-
certainties regarding CV risk profiles of commonly used
NSAIDs, and results of some ongoing research directed
at this are anticipated.
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